Prediction of adverse outcomes in the long-term follow-up period in patients with chronic heart failure who have suffered a myocardial infarction
- Authors: Trusov Y.А.1, Shchukin Y.V.1, Limareva L.V.1
-
Affiliations:
- Samara State Medical University
- Issue: Vol 10, No 2 (2025)
- Pages: 119-127
- Section: Cardiology
- URL: https://journals.rcsi.science/2500-1388/article/view/316063
- DOI: https://doi.org/10.35693/SIM655825
- ID: 316063
Cite item
Abstract
Aim – to determine the prognostic significance of global longitudinal strain of the left ventricle (GLS) and soluble stimulating growth factor (sST2) in patients with chronic heart failure (CHF) after myocardial infarction (MI) in the annual follow-up period.
Material and methods. The study included 96 patients with CHF who were hospitalized with acute MI. All subjects underwent speckle-tracking echocardiography and determination of concentrations of sST2, vascular endothelial growth factor (VEGF), N-terminal pro-brain natriuretic peptide (NT-proBNP) and C-reactive protein (CRP). After 12 months patients were assessed for cases of stroke, recurrent myocardial infarction, hospitalization for unstable angina or decompensation of CHF, and cardiovascular death, forming a combined endpoint (CEP).
Results. The development of CEP was registered in 44 (45.8%) patients with initially lower left ventricular ejection fraction and GLS, higher left ventricular myocardial mass index, index of impaired local contractility, basal diameter of the excretory tract, as well as a higher score on the Syntax scale and concentrations of CRP, NT-proBNP and sST2. During the ROC-analysis for the development of CEP, optimal thresholds for sST2 and NT proBNP were determined, which were 36.1 ng/ml and 427 pg/ml, respectively. The multifactorial analysis made it possible to develop a mathematical model for predicting adverse outcomes within 12 months after MI, which included such indicators as GLS – odds ratio (OR) 0.51 (0.39; 0.72), the number of points on the Syntax scale – OR 3.05 (2.2; 6.8), concentrations of NTproBNP – OR 2.9 (1.45; 5.1) and sST2 – OR 3.3 (1.65; 7.51).
Conclusion. The developed prognostic model includes factors reflecting various links in the pathogenesis of CHF, which provides an integrated approach to assessing the risks of recurrent cardiovascular events after MI.
Full Text
##article.viewOnOriginalSite##About the authors
Yurii А. Trusov
Samara State Medical University
Author for correspondence.
Email: yu.a.trusov@samsmu.ru
ORCID iD: 0000-0001-6407-3880
MD, cardiologist at the Clinics of SamSMU, assistant at the Department of Propaedeutic Therapy with a course in cardiology
Russian Federation, SamaraYurii V. Shchukin
Samara State Medical University
Email: yu.v.shchukin@samsmu.ru
ORCID iD: 0000-0003-0387-8356
MD, Dr. Sci. (Medicine), Professor, Professor of the Department of Propaedeutic Therapy with a course in Cardiology
Russian Federation, SamaraLarisa V. Limareva
Samara State Medical University
Email: l.v.limareva@samsmu.ru
ORCID iD: 0000-0003-4529-5896
MD, Dr. Sci. (Medicine), Head of the Laboratory of Flow Cytometry
Russian Federation, SamaraReferences
- Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-1356. doi: 10.1002/ejhf.1858
- Ignatieva VI, Kontsevaya AV, Lukyanov MM, et al. Cost-effectiveness analysis of increasing drug therapy coverage for patients with coronary artery disease in combination with atrial fibrillation and heart failure. Cardiovascular Therapy and Prevention. 2024;23(4):3950. [Игнатьева В.И., Концевая А.В., Лукьянов М.М., и др. Клинико-экономический анализ увеличения охвата лекарственной терапией пациентов с ишемической болезнью сердца в сочетании с фибрилляцией предсердий и хронической сердечной недостаточностью. Кардиоваскулярная терапия и профилактика. 2024;23(4):3950]. doi: 10.15829/1728-8800-2024-3950
- Roger VL. Epidemiology of Heart Failure: A Contemporary Perspective. Circ Res. 2021;128(10):1421-1434. doi: 10.1161/CIRCRESAHA.121.318172
- Caunite L, Myagmardorj R, Galloo X, et al. Prognostic Value of Follow-up Measures of Left Ventricular Global Longitudinal Strain in Patients With ST-Segment Elevation Myocardial Infarction. J Am Soc Echocardiogr. 2024;37(7):666-673. doi: 10.1016/j.echo.2024.03.007
- D’Ávila LBO, Lima ACGBD, Milani M, et al. Left ventricular global longitudinal strain and cardiorespiratory fitness in patients with heart failure: Systematic review and meta-analysis. Hellenic J Cardiol. 2024;79:58-69. doi: 10.1016/j.hjc.2023.09.010
- Janwetchasil P, Yindeengam A, Krittayaphong R. Prognostic value of global longitudinal strain in patients with preserved left ventricular systolic function: A cardiac magnetic resonance real-world study. J Cardiovasc Magn Reson. 2024;26(2):101057. doi: 10.1016/j.jocmr.2024.101057
- Jenkins WS, Roger VL, Jaffe AS, et al. Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective. Am J Med. 2017;130(9):1112.e9-1112.e15. doi: 10.1016/j.amjmed.2017.02.034
- Felker GM, Anstrom KJ, Adams KF, et al. Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2017;318(8):713. doi: 10.1001/jama.2017.10565
- Khamitova AF, Lakman IA, Akhmetvaleev RR, et al. Multifactor predictive model in patients with myocardial infarction based on modern biomarkers. Kardiologiia. 2020;60(3):14-20. [Хамитова А.Ф., Лакман И.А., Ахметвалеев Р.Р., и др. Многофакторная прогностическая модель у пациентов с инфарктом миокарда в отдаленном периоде на основе современных биомаркеров. Кардиология. 2020;60(3):14-20]. doi: 10.18087/cardio.2020.3.2593
- Clerico A, Emdin M. Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review. Clin Chem. 2004;50(1):33-50. doi: 10.1373/clinchem.2003.024760
- Riccardi M, Myhre PL, Zelniker TA, et al. Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide. JCDD. 2023;10(11):468. doi: 10.3390/jcdd10110468
- Barbarash OL, Duplyakov DV, Zateischikov DA, et al. 2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. Russian Journal of Cardiology. 2021;26(4):4449. [Барбараш О.Л., Дупляков Д.В., Затейщиков Д.А., и др. Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(4):4449]. doi: 10.15829/1560-4071-2021-4449
- Russian society of cardiology. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):4103. [Российское кардиологическое общество. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4103]. doi: 10.15829/29/1560-4071-2020-4103
- Russian society of cardiology. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. [Российское кардиологическое общество (РКО). Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. doi: 10.15829/1560-4071-2020-4083
- Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. doi: 10.1016/j.echo.2014.10.003
- McDonagh TA, Metra M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2024;26(1):5-17. doi: 10.1002/ejhf.3024
- Chuda A, Banach M, Maciejewski M, Bielecka-Dabrowa A. Role of confirmed and potential predictors of an unfavorable outcome in heart failure in everyday clinical practice. Ir J Med Sci. 2022;191(1):213-227. doi: 10.1007/s11845-020-02477-z
- Oleinikov VE, Golubeva AV, Galimskaya VA, et al. Early markers of pathological left ventricular remodeling in patients after ST-elevation myocardial infarction according to speckle-tracking echocardiography. Russian Journal of Cardiology. 2022;27(6):4837. [Олейников В.Э., Голубева А.В., Галимская В.А., Бабина А.В., Донецкая Н.А., и др. Ранние маркеры формирования патологического ремоделирования левого желудочка у больных после инфаркта миокарда с подъемом сегмента ST по результатам speckle tracking эхокардиографии. Российский кардиологический журнал. 2022;27(6):4837]. doi: 10.15829/1560-4071-2022-4837
- Aimo A, Vergaro G, Passino C, et al. Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. JACC Heart Failure. 2017;5(4):280-286. doi: 10.1016/j.jchf.2016.09.010
- Bière L, Garcia G, Guillou S, et al. ST2 as a predictor of late ventricular remodeling after myocardial infarction. Int J Cardiol. 2018;259:40-42. doi: 10.1016/j.ijcard.2018.02.058
- Guan XQ, Guan L, Cheng G, et al. Examining the Long-Term Prognostic Significance of Serum sST2: Influence of Myocardial Infarction History and Subgroup Level Standardization. J Inflamm Res. 2024;17:7733-7744. doi: 10.2147/JIR.S482475
- Pascual-Figal DA, Manzano-Fernández S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail. 2011;13(7):718-725. doi: 10.1093/eurjhf/hfr047
- Clemente G, Soldano JS, Tuttolomondo A. Heart Failure: Is There an Ideal Biomarker? Rev Cardiovasc Med. 2023;24(11):310. doi: 10.31083/j.rcm2411310
Supplementary files
